迈克生物
(300463)
| 流通市值：62.91亿 | | | 总市值：77.78亿 |
| 流通股本：4.95亿 | | | 总股本：6.12亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 616,367,154.02 | 2,895,769,512.02 | 2,115,080,245.6 | 1,380,723,264.24 |
| 营业收入 | 616,367,154.02 | 2,895,769,512.02 | 2,115,080,245.6 | 1,380,723,264.24 |
| 二、营业总成本 | 483,286,866.6 | 2,506,578,260.55 | 1,749,690,942.2 | 1,148,444,030.53 |
| 营业成本 | 262,495,245.94 | 1,295,317,800.53 | 953,202,472.49 | 643,702,353.97 |
| 税金及附加 | 4,033,322.9 | 27,142,111.91 | 17,008,337.33 | 12,171,343.82 |
| 销售费用 | 120,714,364.34 | 652,407,225.96 | 428,465,863.31 | 286,480,979.67 |
| 管理费用 | 32,691,837.69 | 184,234,096.64 | 117,538,742.43 | 69,368,302.92 |
| 研发费用 | 59,524,079.57 | 324,166,528.78 | 217,166,769.19 | 128,572,930.9 |
| 财务费用 | 3,828,016.16 | 23,310,496.73 | 16,308,757.45 | 8,148,119.25 |
| 其中:利息费用 | 5,949,090.27 | 33,532,981.81 | 24,642,035.56 | 15,467,958.79 |
| 其中:利息收入 | 1,835,245.61 | 10,030,794.17 | 7,654,601.33 | 4,910,976.58 |
| 加:公允价值变动收益 | -1,583,386.21 | -7,076,745.18 | -15,391,689.84 | -8,702,955.62 |
| 加:投资收益 | 1,850,226.43 | 8,592,386.93 | 9,921,265.41 | 7,904,536.27 |
| 资产处置收益 | -1,384,763.4 | -4,165,350.13 | -3,150,142.2 | -2,796,308.47 |
| 资产减值损失(新) | -93,684.63 | -58,036,538.66 | -54,331,667.94 | -49,417,652.05 |
| 信用减值损失(新) | -4,863,951.07 | -36,373,435.06 | -19,072,114.87 | -1,684,122.56 |
| 其他收益 | 9,440,505.85 | 39,013,186.93 | 22,681,210.51 | 10,824,817.57 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 136,445,234.39 | 331,144,756.3 | 306,046,164.47 | 188,407,548.85 |
| 加:营业外收入 | 73,568.98 | 378,125.58 | 326,022.71 | 134,745.26 |
| 减:营业外支出 | 535,221.1 | 26,153,908.19 | 10,767,520.3 | 6,035,061.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 135,983,582.27 | 305,368,973.69 | 295,604,666.88 | 182,507,232.46 |
| 减:所得税费用 | 11,739,756.16 | 689,896.99 | 27,572,495.12 | 10,780,348.86 |
| 六、净利润 | 124,243,826.11 | 304,679,076.7 | 268,032,171.76 | 171,726,883.6 |
| 持续经营净利润 | 124,243,826.11 | 304,679,076.7 | 268,032,171.76 | 171,726,883.6 |
| 归属于母公司股东的净利润 | 120,442,248.9 | 312,618,556.85 | 268,677,386.46 | 174,836,659.46 |
| 少数股东损益 | 3,801,577.21 | -7,939,480.15 | -645,214.7 | -3,109,775.86 |
| (一)基本每股收益 | 0.2 | 0.51 | 0.44 | 0.29 |
| (二)稀释每股收益 | 0.2 | 0.51 | 0.44 | 0.29 |
| 八、其他综合收益 | -363,649.36 | -8,400,942.55 | -16,909,056.6 | -9,123,716.24 |
| 归属于母公司股东的其他综合收益 | -363,649.36 | -8,400,942.55 | -16,909,056.6 | -9,123,716.24 |
| 九、综合收益总额 | 123,880,176.75 | 296,278,134.15 | 251,123,115.16 | 162,603,167.36 |
| 归属于母公司股东的综合收益总额 | 120,078,599.54 | 304,217,614.3 | 251,768,329.86 | 165,712,943.22 |
| 归属于少数股东的综合收益总额 | 3,801,577.21 | -7,939,480.15 | -645,214.7 | -3,109,775.86 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-26 | 2023-07-29 |
| 审计意见(境内) | | 标准无保留意见 | | |